IMMUNOENGINE

Neoantigen prediction platform

Fuelled by advances in genomic and proteomic technologies, personal promises to innovate cancer therapy and to target previously untreatable tumors. A critical part of developing such strategies is finding those antigens that have the potential to elicit a sufficiently strong immune response. For the past years, myNEO Therapeutics has been developing its antigen prediction platform, providing a robust pipeline focused on the identification and prediction of antigen targets within the full genome of tumors.

The process starts with the collection of both patient blood and a tumor biopsy.

Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.

Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called ‘neoX’.

Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides

In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).

IMMUNOENGINE

Neoantigen prediction platform

Fuelled by advances in genomic and proteomic technologies, personal promises to innovate cancer therapy and to target previously untreatable tumors. A critical part of developing such strategies is finding those antigens that have the potential to elicit a sufficiently strong immune response. For the past myNEO Therapeutics has been developing its antigen prediction platform, providing a robust pipeline focused on the identification and prediction of antigen targets within the full genome of tumors.

The process starts with the collection of both patient blood and a tumor biopsy.

Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.

Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called ‘neoX’.

Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides

In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).

OUR PROPRIETARY ALGORITHMS

Rapid selection of the most optimal targets

smORFin

Best-in-class algorithm specifically trained to identify smORFs in transcripts and to assess their coding potential for camyotopes.

smorfin_animation

neoMS

Best-in-class presentation prediction algorithm that takes into account the full antigen processing pathway.

neoMS_animation

neoIM

First-in-class immunogenicity prediction algorithm that predicts the activation of CD8+ T-cells by a given epitope.

neoIM_animation

OUR PUBLICATIONS

Scientific papers

neoantigen_directed_therapeutics_in_the_clinic

Neoantigen-directed therapeutics in the clinic: where are we?

Where are we: Trends in Cancer – 2023

challenges_in_neoantigen_directed_therapeutics

Challenges in neoantigen-directed therapeutics

Challenges: Cancer Cell – 2022

improving_t_cell_mediated_immunogenic_epitope_identification

Improving T-cell mediated immunogenic epitope identification via machine learning: the neoIM model

neoIM model: BioRxiv – 2022

neoMS_paper

neoMS: attention-based prediction of MHC-I epitope presentation

neoMS: BioRxiv – 2022

MCB_paper

MCB: Methods behind
neoantigen prediction
for personalized
anticancer vaccines

Methods in Cell Biology – 2023

Whitepapers

immunosurveillance

Camyotopes: a novel class of tumor targets

liquid_biopsies

Liquid biopsies in personalized medicine – future and pitfalls

more_to_the_genome

There is more to the genome: increasing the range of actionable high-confidence neoantigen discovery by whole genome sequencing

optimal_neoantigen_prediction_and_selection

Optimal neoantigen prediction and selection – where’s the sweet spot?

gut_microbiome

How the gut microbiome affects cancer immunotherapy

beyond_snvs_indels

Beyond SNVs and indels for neoantigen prediction in cold tumors

promise_of_personalized_cancer_vaccination

The promise of personalized cancer vaccination

holy_grail

Is immunotherapy the holy grail in the fight against cancer

immunosurveillance

Immunosurveillance and the importance of CD4 T-cells in cancers

logo - myneo-02

Innovating immunotherapies,
transforming tomorrow

Subscribe to our newsletter

Get the latest news & updates about myNEO Therapeutics

Home

About us

Products

Technology

Partners

Services

Contact

Quick links

Publications

Latest news

Privacy statement

Terms of use

Careers

Cookie statement

We use cookies to enhance your browsing experience and provide analytics. By continuing to use this website, you agree to our use of cookies. For more information, please read our privacy statement.

myNEO BV

Ottergemsesteenweg-Zuid 808 B511, 9000 Ghent, East-Flanders
Belgium (BE0715710837)

Design by

wimmees_log
© 2024 - myNEO